HIV vaccine preventing healthy cells' infection

"We have used an innovative approach, combining protein engineering, specific vaccine formulation and a combination of routes of administration, [nasal] and intramuscular," explains Nicolas Mouz, chief scientific officer at PX'Therapeutics, one of the project partners. The company is also providing services, in protein engineering research and manufacturing and it is located in Grenoble, France.

There have been many trials since the discovery of the virus, in the early 1980s, to create both a cure for infected people and a preventative therapy to stop the contagion. "This gp41 protein from the virus envelope is not an absolute novelty in the long history of anti HIV vaccine development," says Alexandru Rafila, Chairman of the Romanian Society for Microbiology in Bucharest. "But it is a meaningful approach in protein design that could be given as a vaccine so that it triggers an immune response."

The trouble is that the virus targets not only the lymphocyte cells, which include T cells -- a key component of the body's immune system helping to fight diseases -- but also other immune system cells. The latter are not exclusively infected through the gp41 protein but also through other mechanisms. "An efficient vaccine should hamper the infection of any other cells," Rafila tells youris.com.

Other experts concur that the diversity of HIV and its enormous capacity to mutate are some of the main challenges for vaccine development. "The idea basically is that a vaccine should induce antibodies T cells immune response, that would neutralise HIV in all of its forms," explains Ulrich Fruth, vaccine development and evaluation team leader at the World Health Organisation, in Geneva, Switzerland.

Even though Fruth considers the project strategy an excellent approach, chances of success of this vaccine are difficult to foresee. "We just don't know," he says, "The only thing we know is that we have more experience on human trials. The animal models used so far were not very predictive. We need human clinical trial in order to decide which vaccine to take forward," he concludes. The vaccine is in its first stage of clinical safety's studies, which proved to have a relatively weak effect. It is too early to provide an explanation to such results.

In addition, Fruth points to a minor limitation of this vaccine, namely that it focuses on the induction of antibodies. He concludes: "we think that for a successful protection we may need [to target] both: antibodies and T cells. The role that I would see for such a vaccine would probably be in combination with the components that induce T cell immune response. So, [what may proved useful is to test] a combination vaccine [and] not a standalone one."